Heinz Schwer Ph.D.

Heinz Schwer, PhD, MBA has a diverse work experience spanning over several industries. Heinz is currently the Managing Director/Chief Business Officer at VERAXA Biotech GmbH and a Senior Investment Advisor at SHS Capital. Previously, they served as the Managing Director at EMBL Ventures and took a sabbatical leave in 2018. Prior to that, they held various leadership positions including CEO at ViraTherapeutics and Lanthio Pharma. Heinz also worked as a Senior Director at Morphosys AG and held multiple roles at Sloning Biotechnology GmbH, including CEO, COO, and Head of R&D. Heinz started their career as a Chemikant at British Petrol AG before pursuing a postdoctoral fellowship at Harvard University, Medical School.

Heinz Schwer, PhD, MBA has an extensive education history. Heinz started their academic journey in 1987 at Berufsoberschule, where they obtained their Hochschulreife. Following this, they attended the University of Regensburg from 1989 to 1995 and achieved a Dipl. Chem. degree with a focus on Genomics and Lipid Metabolism. Heinz then pursued further studies at Harvard Medical School from 1999 to 2001, specializing in Genetics, specifically in the field of Leukemia. Continuing their education, Heinz Schwer earned a Dr. rer. nat. degree in Chemistry at the University of Regensburg from 1995 to 1999. Lastly, they completed an MBA degree at Henley Business School from 2003 to 2007.